Tradestie Institutional Equity Comparison Engine

IMMX vs CING โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IMMX Overall Edge

IMMX Captures Institutional Edge (3โ€“0 Pillars ยท 5โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Immix Biopharma, Inc. Common Stock (IMMX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, IMMX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CING at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, IMMX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
IMMX N/M vs CING N/M Fwd P/E
Growth & Margin Winner IMMX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner IMMX
1Y +71.7% vs +35.4% ยท 52W Pos 32% vs 18%
Options & Structure Winner IMMX
BREAKDOWN (17th %ile IV) vs BREAKDOWN (16th %ile IV)
IMMX NASDAQ
Immix Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$7.23
-3.34% 1D
Market Cap $657.1M
1M Return -12.04%
1Y Return +71.73%
Forward P/E N/M
Unified AI Score
53.1 / 100 HOLD
Tech 57.0 Fund 57.0 Flow 68.0 Mom 64.0
CING NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.72
+26.0% 1D
Market Cap $62.5M
1M Return +8.37%
1Y Return +35.39%
Forward P/E N/M
Unified AI Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: IMMX +71.73% CING +35.39% Spread: +36.34 pp (IMMX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
IMMX TTM Op. Margin: 0.0% CING TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMMX vs CING. Trailing 12-month operating profitability (IMMX 0.0% vs CING 0.0%) and valuation multiples (IMMX N/M vs CING N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: IMMX (5) vs CING (0)
Institutional Metric IMMX CING Criterion Row Winner
Market Capitalization Scale $657.1M $62.5M Larger Scale IMMX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -27.0% -198.7% Higher ROE IMMX
52-Week Range Position Momentum 32% ($4โ€“$15) 18% ($3โ€“$12) Stronger Trend IMMX
Beta / 30D Volatility Risk Regime 1.83ฮฒ ยท 83% Vol 1.07ฮฒ ยท 121% Vol Lower Realized Risk IMMX
Unified Institutional Score Composite Signal 53.1 / 100 (HOLD) 44.8 / 100 (HOLD) Higher Composite IMMX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full IMMX vs CING Buy Guide
IMMX BREAKDOWN
59d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live IMMX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CING BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live CING Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither IMMX nor CING registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.